SR 16234

Drug Profile

SR 16234

Alternative Names: SR16234; TAS-108

Latest Information Update: 12 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SRI International
  • Developer SRI International; Taiho Pharmaceutical; Tottori University Hospital
  • Class Antineoplastics; Estradiol congeners; Estrenes
  • Mechanism of Action Selective estrogen receptor degraders; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometriosis
  • No development reported Breast cancer

Most Recent Events

  • 31 Dec 2016 SRI International completes a phase II trial in Endometriosis in Japan (PO) (UMIN000019193)
  • 01 Oct 2015 Tottori University Hospital plans a phase II trial for Endometriosis in Japan (UMIN000019193)
  • 11 Sep 2014 No development reported - Phase-II for Breast cancer (Late-stage disease, Metastatic disease) in Russia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top